

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [ICC International Cannabis Corp.](#) (the "Issuer").

Trading Symbol: [WRLD.U](#)

Number of Outstanding Listed Securities: [705,355,955](#) as of [July 31, 2019](#).

Date: [August 01, 2019](#) (for the month of **July 2019**)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[The Issuer continues to evaluate potential marijuana projects and cannabis related companies for potential acquisition and growth. The Issuer continues to concentrate on assembling a robust portfolio of licences globally specializing in the cultivation, extraction and distribution of medical cannabis and CBD products with a specific emphasis on both the European Union and Latin American](#)

regions, and a keen interest in Africa and Australasia, Southeast Asia, and the Pacific Rim.

2. Provide a general overview and discussion of the activities of management.

During the month of **July 2019**, the Issuer:

- o Entered into an exclusive supply and commercial rights agreement with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals.
 - o Issued 318,757 shares pursuant to a shares for services transaction.
 - o Entered into a cannabinoid pharmaceutical advisory agreement, alongside Biotti Technologies Corp., with Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alexandros Makriyannis, PhD.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable to the Issuer for the month of July 2019.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable to the Issuer for the month of July 2019.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On **July 18, 2019**, the Issuer announced that it had entered into an exclusive supply and commercial rights agreement (the "Agreement") with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals ("NUBU").

Under the terms of the Agreement, the Issuer will supply NUBU with a suite of full-spectrum pharmaceutical grade medical cannabis products.

The Issuer will leverage its existing brand portfolio, European GMP-certified processing facilities and extraction ready inventories to maximize margins and profitability, while servicing New Zealand's high value patient population.

Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand's high-value medical cannabis industry. In partnership with the Issuer, NUBU is now equipped with the best in class product formulation and

supply chain infrastructure required to deliver reputable and clinically effective medicinal cannabis products into the New Zealand marketplace. Earlier this year NUBU was awarded a License to Deal in Controlled Drugs by New Zealand's Ministry of Health, and a License to Sell Medicines Wholesale, which will allow the company to import and distribute ICC manufactured THC/CBD products ahead of other local market participants.

A finder's fee is payable on this transaction.

On **July 18, 2019** the Issuer issued a total of 318,757 common shares of the Company to JYT Partners Limited (the "Consultant"), in consideration for services rendered pursuant to the terms of a Consulting Agreement (the "Agreement") entered into with the Company and invoices received by the Company dated September 30, 2018 to June 30, 2019.

The common shares are being issued as a shares for services transaction.

Pursuant to the terms of the Agreement:

The deemed price of 44,118 common shares is CDN\$0.68, which was calculated by using the volume weighted average closing share price on the last 5 trading days of September 2018. The deemed price of 80,550 common shares is USD\$0.273, which was calculated by using the volume weighted average closing share price on the last 5 trading days of December 2018. The deemed price of 66,027 common shares is USD\$0.34, which was calculated by using the volume weighted average closing share price on the last 5 trading days of March 2019. The deemed price of 128,062 common shares is USD\$0.179, which was calculated by using the volume weighted average closing share price on the last 5 trading days of June 2019.

The Company confirms that the securities issued have not created a new Control Person of the Issuer.

On **July 23, 2019**, the Issuer, alongside Biotii Technologies Corp. ("Biotii"), entered into a cannabinoid pharmaceutical advisory agreement (the "Agreement") with Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alexandros Makriyannis, PhD ("Dr. Makriyannis"). A professor of Chemistry and Chemical Biology in the Department of Medicinal Chemistry at Northeastern University, Dr. Makriyannis is credited with numerous scientific cannabinoid-centric achievements, including the discovery of cannabinoid receptor antagonists, as well as pioneering in metabolically stable endocannabinoids.

Dr. Makriyannis will champion the Company's pursuit of biosynthesizing cannabinoids identical to those found in nature, with the objective of standardizing pharmacological effects within the human endocannabinoid system. Highly specialized knowledge of cannabinoid biochemistry, as well as the macro human endocannabinoid system equips the Issuer and Biotii with a

first mover competitive advantage to economically scale its synthesized cannabinoid platform.

By 2020, the Issuer and Biotii intends to establish processes to efficiently mass-produce CBD/THC in quantities of hundreds of metric tonnes per annum, which boast:

- Stable and consistent yields;
- Pharmaceutical-grade purities; and,
- The lowest production costs in the space.

Armed with a successful track record of generating cannabinoid centric intellectual property (“IP”), including the authoring of 37 related patents within the United States, Dr. Makriyannis will assist in guiding ICC funded Biotii with their corporate mandate of securing a robust portfolio of defendable IP. Dr. Makriyannis is exclusively qualified to ensure Biotii’s retains its competitive advantage as one of the first innovators to economically biosynthesize cannabinoids at industrial scale.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable to the Issuer for the month of **July 2019**.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable to the Issuer for the month of **July 2019**.

8. Describe the acquisition of new customers or loss of customers.

Not applicable to the Issuer for the month of **July 2019**.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable to the Issuer for the month of **July 2019**.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable to the Issuer for the month of **July 2019**.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable to the Issuer for the month of **July 2019**.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable to the Issuer for the month of **July 2019**.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable to the Issuer for the month of **July 2019**.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	2,000,000	Shares were issued as finder's fees pursuant to a Supply Agreement.	Not Applicable
Common Shares	318,757	Shares were issued pursuant to a Shares for Services Transaction.	Not Applicable
Common Shares	150,000	Shares issued pursuant to a warrant exercise (150,000 warrants were exercisable at a price of CDN\$0.07)	General working capital purposes.

15. Provide details of any loans to or by Related Persons.

Not applicable to the Issuer for the month of **July 2019**.

16. Provide details of any changes in directors, officers or committee members.

Not applicable to the Issuer for the month of **July 2019**.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion & Analysis dated January 28, 2019 (the "MD&A"). The MD&A is available on the Issuer's SEDAR profile at www.sedar.com.

[the balance of this page is intentionally blank]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 01, 2019.

Eugene Beukman
Name of Director or Senior
Officer

"Eugene Beukman"
Signature

Director
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	YY/MM/DD
ICC International Cannabis Corp		July 2019	19/08/01
Issuer Address			
810 – 789 West Pender Street			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 1H2		604-687-3141	604-687-2308
Contact Name		Contact Position	Contact Telephone No.
Eugene Beukman		Director	604-782-4191
Contact Email Address		Web Site Address	
ebeukman@pendergroup.ca		N/A	